Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COLCOHIV
2024-520346-39-00Phase 2Authorised
- Sponsor
- FIBHULP
- Start
- Apr 2025
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in human immunodeficiency virus infection (HIV), coronary arteriosclerosis and cardiac morbidity comparing Colchicine with Placebo (2 arms). Primary endpoint: Percent change from baseline of mean Fat Attenuation Index score across the 3 main coronary arteries. Planned start Apr 2025; status: authorised.
02
Drugs
colchicine
03
Conditions
human immunodeficiency virus infection (HIV)coronary arteriosclerosiscardiac morbidity
Beyond the preview
Go deeper on 2024-520346-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-520346-39-00.